

AM06™ Akkermansia Muciniphila
AM06™ Akkermansia Muciniphila is a unique probiotic. It has shown potential for treatment and prevention in various disease models.
Unique Advantages of AM06
Our probiotic products, with their exceptional qualities, support a healthier lifestyle.
AM06 Safety
AM06™ has been extensively tested for safety, showing no virulence or resistance genes, confirming its high safety and suitability for use based on comprehensive genome sequencing and EFSA guidelines.
AM06 has undergone comprehensive toxicological and safety studies, with its inactivation process eliminating the risk of live bacterial infection, thus enhancing its applicability and safety profile. Full genome sequencing of AM06 meets the 2021 EFSA guidelines for whole-genome analysis, including preliminary assessments of virulence genes, resistance genes, and mobile genetic elements. The results confirm that AM06 contains no virulence or resistance genes, affirming its safety for use.
Patents
22 Patents
22 patent applications have been filed for AM06™, with six already granted.
Articles
Articles
Related research findings have been published in multiple journals.
Articles list
- Hou, Fengyi et al. “Safety Evaluation and Probiotic Potency Screening of Akkermansia muciniphila Strains Isolated from Human Feces and Breast Milk.” Microbiology spectrum, vol. 11,2 e0336122. 14 Feb. 2023, doi:10.1128/spectrum.03361-22
- Li, Tao et al. “Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells.” Frontiers in immunology vol. 13 1047570. 1 Dec. 2022, doi:10.3389/fimmu.2022.104757
- Su Peizhu et al.“Isolation and identification of a strain of Akkermansia muciniphila from healthy human colostrum”,Journal of microbiology vol. doi:10.3969/j.issn.1005-7021.2024.05.009
Phone: 0086-20-82258826
Email: public@zypharm.com.cn
Fax: 0086-20-82515346
Address: 3rd Floor, Building A, No. 2 Ruitai Road, Huangpu District, Guangzhou, Guangdong, China